A recent study from Stem Cell Program, Boston Children’s Hospital, Boston, MA, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA; and Harvard Stem Cell Institute, Cambridge, MA, USA shows that “The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation.” This study was published in the July 31 2014 Cancer Cell (The number 1 journal in basic Cancer biology) by Prof Fernando D. Camargo, Annie M. Tremblay, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Differentiation Therapy for Embryonal Rhabdomyosarcoma: Tumor suppressor PTEN inhibits the activation of satellite cells and the development of Rhabdomyosarcoma via down regulation of its target gene. This study suggests that PTEN, by increasing the expression of MYOD1 and MEF2, it may promote Embryonal Rhabdomyosarcoma differentiation. Together, this study suggests that pharmacological formulations encompassing“PTEN activators” may be used to treat Embryonal Rhabdomyosarcoma.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Differentiation Therapy for Embryonal Rhabdomyosarcoma: PTEN inhibits the activation of satellite cells and the development of Rhabdomyosarcoma via down regulation of its target gene, 5/August/2014, 11.11 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
